Literature DB >> 9158046

Arteether: risks of two-week administration in Macaca mulatta.

J M Petras1, D E Kyle, M Gettayacamin, G D Young, R A Bauman, H K Webster, K D Corcoran, J O Peggins, M A Vane, T G Brewer.   

Abstract

Male rhesus monkeys (Macaca mulatta) were administered daily doses of the antimalarial drug arteether. The 14-day treated group received either 24 mg/kg/day, 16 mg/kg/day, or 8 mg/kg/day. The seven-day treatment group received either 24 mg/kg/day or 8 mg/kg/day. All control cases in each group received the sesame oil vehicle alone. Neurologic signs were absent for animals in the seven and 14-day treatment groups except for one monkey which showed diffuse piloerection on day 14, and another monkey receiving 24 mg/kg/day for seven days showed mild lethargy after the fourth day. Mild, sporadic anorexia was noted in all animals by day 14, and a single animal showed diffuse piloerection on day 14. Surgical anesthesia preceded killing by exsanguination and was accompanied by perfusion fixation of the central nervous system. Brain sections were cut and then stained for study by light microscopy. Evidence of neuronal pathology, both descriptive and numerical, was collected. The neuroanatomic and neuropathologic findings demonstrated that arteether produced extensive brainstem injury when administered for 14 days. The magnitude of brainstem neurotoxicity was dose-dependent, where injury was greatest at the 24 mg/kg/day dose level, less at the 16 mg/kg/day dose level, and least at the 8 mg/kg/day dose level. Arteether induced multiple systems injury to brainstem nuclei of 1) the reticular formation (cranial and caudal pontine nuclei, and medullary gigantocellular and paragigantocellular nuclei); 2) the vestibular system (medial, descending, superior, and lateral nuclei); and 3) the auditory system (superior olivary nuclear complex and trapezoid nuclear complex). The vestibular nuclei and the reticular formation were most severely injured, with the auditory system affected less. The cranial nerve nuclei (somatic and splanchnic) appeared to escape damage, with the exception of the abducens nerve nucleus. The same brainstem nuclear groups of seven-day treated monkeys appeared normal. The statistical data are concordant with the descriptive data in demonstrating neurotoxic effects. In summary, no neurologic deficits were detected in any of the vehicle control monkeys (14-day and seven-day cases). Monkeys in the 14-day treatment group were free of clinical neurologic signs throughout the first week. At day 14, fine horizontal nystagmus was seen in one monkey, and another monkey exhibited diffuse piloerection. Monkeys in the seven-day treatment group were free of clinical neurologic signs except for one case. This monkey was treated with 24/mg/kg/day of arteether and exhibited lethargy after the fourth day. These indications of dysfunction arose too late to be practical indicators of neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9158046     DOI: 10.4269/ajtmh.1997.56.390

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  13 in total

1.  Establishment of an in vitro screening model for neurodegeneration induced by antimalarial drugs of the artemisinin-type..

Authors:  G Schmuck; R K Haynes
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 2.  Safety assessment of peroxide antimalarials: clinical and chemical perspectives.

Authors:  B K Park; P M O'Neill; J L Maggs; M Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

3.  A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria.

Authors:  Y Suputtamongkol; P N Newton; B Angus; P Teja-Isavadharm; D Keeratithakul; M Rasameesoraj; S Pukrittayakamee; N J White
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

4.  In vitro activity of lumefantrine (benflumetol) against clinical isolates of Plasmodium falciparum in Yaoundé, Cameroon.

Authors:  L K Basco; J Bickii; P Ringwald
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 5.  Nanomedicines for Malaria Chemotherapy: Encapsulation vs. Polymer Therapeutics.

Authors:  Sindisiwe Mvango; William M R Matshe; Abideen O Balogun; Lynne A Pilcher; Mohammed O Balogun
Journal:  Pharm Res       Date:  2018-10-15       Impact factor: 4.200

6.  Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria.

Authors:  Gabriel Carrasquilla; Clemencia Barón; Edwin M Monsell; Marc Cousin; Verena Walter; Gilbert Lefèvre; Oliver Sander; Laurel M Fisher
Journal:  Am J Trop Med Hyg       Date:  2012-01       Impact factor: 2.345

7.  Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria.

Authors:  P Newton; Y Suputtamongkol; P Teja-Isavadharm; S Pukrittayakamee; V Navaratnam; I Bates; N White
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  Neurotoxic mode of action of artemisinin.

Authors:  Gabriele Schmuck; Elke Roehrdanz; Richard K Haynes; Regine Kahl
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria.

Authors:  Timothy M E Davis; Tran Quang Binh; Kenneth F Ilett; Kevin T Batty; Hoang Lan Phuöng; Gregory M Chiswell; Vu Duong Bich Phuong; Cindy Agus
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  Arteether toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and multiple doses.

Authors:  Q G Li; R P Brueckner; J O Peggins; K M Trotman; T G Brewer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.569

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.